Media Centre

Find out more about the latest news at Virtus Health, including medical breakthroughs in fertility treatment, growth within our network, and research papers.

Contact Us for comment on recent developments in the industry or interview requests.

Virtus Acquires IDS Pathology Laboratory, Sydney

Sydney, Australia – Virtus Health (“Virtus”, ASX:VRT), Australia’s largest fertility services provider, has agreed terms to acquire the business and certain assets of Independent Diagnostic Services (IDS), a general category pathology laboratory based in Sydney, Australia, as part of its strategy to expand and strengthen its diagnostics services. Completion of the acquisition is expected to take place during September 2015 subject to regulatory approval.

Virtus Health Full Year Financial Results FY2015

Pro-forma net profit after tax (NPAT) grew 17.2% on the previous year to $32 million, from $27.3 million; pro-forma revenue rose 6.7% on the previous year to $199.9 million, from $187.3 million. Actual (or statutory) revenue from ordinary activities increased 7.9% to $201.2 million from $186.6 million while statutory net profit attributable to the owners of Virtus Health Limited tripled to $30.9million, from $10.1 million.

The first Australians to use Karyomapping genetic testing to avoid passing on life threatening conditions – deliver healthy babies

In an Australian first, two families have delivered healthy babies on the same day (one in Melbourne, the other Sydney) conceived using karyomapping, a new pre-implantation genetic test based on the use of DNA fingerprinting to identify defective genes. Karyomapping was first introduced in Australia in November 2014 by Virtus Health (comprising Melbourne IVF, IVFAustralia, Hunter IVF, Queensland Fertility Group, & TasIVF).

Virtus Grows Revenue and Australian Market Share Despite Weak Local Market Conditions

Highlights

  • Revenue increased by 12.9% to $114.5 million
  • EBITDA increased by 2.6% to $32.8 million
  • Australian segment EBITDA increased by 2.2% to $36.8 million
  • Increased Australian Assisted Reproductive Services (ARS) market share despite sector contraction
  • International operations contribute $10.4 million to revenue
  • Day Hospital and Specialist Diagnostics continue to deliver growth

Key Financial Results

 

Virtus Health Subsidiary Sims Clinic Completes Acquisition of Second Irish Fertility Clinic for €6 Million

Sydney, Australia – Further to the announcement to ASX made on 24 December 2014, Virtus Health (“Virtus”, ASX: VRT), Australia’s largest IVF provider, announces that its 70% owned subsidiary, Sims IVF Clinic, Ireland’s largest IVF provider, has completed the acquisition of Irish fertility centre, the HARI clinic from the Rotunda Hospital in Dublin for €6 million.

Virtus Health Subsidiary Sims IVF Clinic to Acquire Second Irish Fertility Clinic for €6 Million

Sydney, Australia – Virtus Health (“Virtus”, ASX: VRT), Australia’s largest IVF provider, today announced that its 70% owned subsidiary, Sims Clinic has agreed to acquire an Irish fertility centre, the HARI clinic from the Rotunda Hospital in Dublin for €6 million. Virtus expects the transaction will be completed on 31 December 2014.

Virtus Health Opens New Fertility Centre In Singapore

Sydney, Australia – Virtus Health (“Virtus”, ASX: VRT), Australia’s largest IVF provider, is pleased to announce it has opened its first Virtus branded Fertility Centre in Singapore.

Virtus Health Acquires a Majority Stake in Tasmanian IVF Provider, TasIVF for $16M

Sydney, Australia – Virtus Health (“Virtus”, ASX: VRT) Australia’s largest IVF provider today announced it has acquired a 70% share of TasIVF Pty Ltd (“TasIVF”).

The transaction value is $16.0 million on a cash free debt free basis and has been satisfied from existing cash resources and a drawdown of $8m from the group’s bank facilities. For the year to 30 June 2014, TasIVF normalised earnings would have increased Virtus' basic earnings per share by approximately 1.24 cents.

Australian First: New genetic testing set to improve access and outcomes for IVF patients

In an Australian first, Virtus Health comprising Melbourne IVF, Queensland Fertility Group and IVFAustralia has introduced karyomapping, a new genetic test that will significantly improve access to treatment and the chance of a live birth for couples wishing to avoid the transmission of a serious genetic disorder to their children.

Patients who know they are carriers of a genetic disease, for example cystic fibrosis, can have their embryos tested using karyomapping and preimplantation genetic diagnosis (PGD).

Virtus Health Acquires IVF Sunshine Coast Clinic

Sydney, Australia – Virtus Health (“Virtus”, ASX: VRT) Australia’s largest IVF provider today announced it has acquired the remaining 80% share of IVF Sunshine Coast in Queensland, taking full ownership of the clinic.

Career Opportunities

Interested in joining our team? Read about our current opportunities for fertility specialists.
Find out more...

© Virtus Group 2015